The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Duomic platform supports simultaneous single-cell TCR profiling and highly multiplexed functional proteomics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data generated using the Duomic platform, sponsored by IsoPlexis Corporation, demonstrated the ability to connect T-cell receptor diversity to the most functionally potent single cells, according to findings presented at the 2022 AACR annual meeting.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

More cancers being treated with personalized therapies before surgery, National Cancer Database report shows

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account